881 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
SNY Sanofi $43.75 $109.14B Downtrend
Article Searches
Stocks making the biggest move premarket: KMB, HAL, HAS, PII, INTC & more https://www.cnbc.com/2018/10/22/stocks-making-the-biggest-move-premarket-kmb-hal-has-pii-intc--more.html Oct 22, 2018 - Names on the move ahead of the open.
FDA OKs Regeneron and Sanofi's Dupixent for asthma https://seekingalpha.com/news/3399067-fda-oks-regeneron-sanofis-dupixent-asthma?source=feed_news_all Oct 20, 2018 - The FDA approves Regeneron Pharmaceuticals (NASDAQ:REGN) and development partner Sanofi's (NYSE:SNY) DUPIXENT (dupilumab) as add-on maintenance therapy in patients with moderate-to-severe asthma aged
10 'Safer' Dividend Healthcare WallStars Gain 12-23% Per Broker October Targets And Dividends https://seekingalpha.com/article/4211834-10-safer-dividend-healthcare-wallstars-gain-12minus-23-percent-per-broker-october-targets?source=feed_all_articles Oct 16, 2018 - October's top net gain safer Healthcare WallStar is AbbVie. Its projected 23% net gain was 2.3% better than Sanofi's, and 3.4% more than Grifol's result per analyst targets of 10/12/18.WallStars all s
Aimmune teams up with Regeneron and Sanofi in mid-stage peanut allergy study; shares up 1% https://seekingalpha.com/news/3397330-aimmune-teams-regeneron-sanofi-mid-stage-peanut-allergy-study-shares-1-percent?source=feed_news_all Oct 15, 2018 - Aimmune Therapeutics (AIMT +1.3%) is up on light volume on the heels of the initiation of a Phase 2 clinical trial evaluating AR101 with adjunctive DUPIXENT (dupilumab) in peanut-allergy patients.The
Healthcare 16-24% Target Net Gains Pace WallStars For October https://seekingalpha.com/article/4211623-healthcare-16minus-24-percent-target-net-gains-pace-wallstars-october?source=feed_all_articles Oct 15, 2018 - Big pharma drug makers and biotech continued to top the healthcare sector by broker targets. WallStars are distinguished by positive broker target price upsides.The Healthcare sector is comprised of 1
Sanofi eyeing large campus in Cambridge, MA https://seekingalpha.com/news/3397251-sanofi-eyeing-large-campus-cambridge-ma?source=feed_news_all Oct 15, 2018 - The Boston Globe reports that Sanofi's (NYSE:SNY) U.S. unit is planning a major expansion in East Cambridge, MA that may be as large as 400K square feet, enough to house 2K employees. The former rail
Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts http://www.zacks.com/stock/news/327579/merrimack-mack-focuses-on-early-stage-pipeline-and-cost-cuts?cid=CS-ZC-FT-327579 Oct 11, 2018 - Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.
Altimmune Declines Too Much https://seekingalpha.com/article/4210760-altimmune-declines-much?source=feed_sector_healthcare Oct 09, 2018 - Altimmune, Inc. is a clinical stage immunotherapeutics company developing robust and durable immune responses intended for the prevention and treatment of several illnesses.The market is too pessimist
Lexicon Likely Looking At Even More Competition In Type 1 Diabetes https://seekingalpha.com/article/4210037-lexicon-likely-looking-even-competition-type-1-diabetes?source=feed_tag_editors_picks Oct 05, 2018 - Data from Phase III trials of Lilly/Boehringer's Jardiance in Type 1 diabetes supports submission and commercialization, bringing another competitor into the market.Lexicon's sotagliflozin is not out
Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs http://www.zacks.com/stock/news/326050/biotech-stock-roundup-alxn-on-acquisition-spree-fda-nod-for-regn-amgn-drugs?cid=CS-ZC-FT-326050 Oct 03, 2018 - The biotech sector grabs headlines this week with FDA approvals plus licensing and acquisition pacts.

Pages: 123456...89

Page 1>

Related Companies

Name Exchange Price Mkt Cap
LLY Eli Lilly and Company NYSE $105.71 $113.53B
NVO Novo Nordisk A/S NYSE $47.64 $114.84B
BMY Bristol-Myers Squibb Company NYSE $61.3 $100.03B
ABT Abbott Laboratories NYSE $67.67 $118.71B
GSK GlaxoSmithKline PLC NYSE $39.21 $97.25B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Sanofi